DMS-114 Cells
USD 550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Información general
| Descripción | DMS-114 is a human small-cell lung cancer (SCLC) cell line with unique features distinguishing it from other SCLC subtypes. Recent research has indicated that DMS-114, previously classified within the YAP1-expressing SCLC category (SCLC-Y), harbors pathogenic mutations in SMARCA4, an ATPase subunit of the SWI/SNF chromatin-remodeling complex. These mutations are associated with the absence of RB1 mutations, contrary to the typical mutational landscape of SCLC, which commonly features concurrent TP53 and RB1 alterations. This cell line's profile includes reduced expression of SMARCA4 mRNA and protein, contributing to its reclassification as a SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) rather than a traditional SCLC. Morphological assessments have shown that DMS-114 aligns more closely with thoracic SMARCA4-UT, exhibiting traits such as lower neuroendocrine marker expression and a distinctive immunohistochemical profile. The revised classification of DMS-114 as a SMARCA4-deficient malignancy rather than SCLC has significant implications for its use as a preclinical model. It serves as an important resource for studying therapeutic strategies targeting SMARCA4-related pathways and investigating the biology of aggressive thoracic cancers that mimic SCLC. Unlike conventional SCLC, SMARCA4-deficient tumors, including DMS-114, often present with unique gene expression profiles marked by high YAP1 expression, loss of certain neuroendocrine markers, and distinct molecular vulnerabilities. This insight underscores the necessity of comprehensive molecular and histopathological analysis for accurate tumor classification and the development of effective treatment strategies. |
|---|---|
| Organismo | Human |
| Tejido | Lung |
| Enfermedad | Thoracic SMARCA4-deficient undifferentiated tumor |
| Sinónimos | DMS-114, DMS114, Darmouth Medical School 114 |
Características
| Edad | 68 years |
|---|---|
| Género | Male |
| Origen étnico | Caucasian |
| Propiedades de crecimiento | Adherent |
Datos normativos
| Referencia | DMS-114 (Cytion catalog number 305364) |
|---|---|
| Nivel de bioseguridad | 1 |
| NCBI_TaxID | 9606 |
| N.º de acceso de Cellosaurus | CVCL_1174 |
Datos biomoleculares
| Receptores expresados | Epidermal growth factor (EGF), complement (CR3) |
|---|---|
| Expresión de proteínas | Genes expressed: adrenocorticotropin (adrenocorticotropic hormone, ACTH), bombesin, glucagon, 17 beta estradiol, oxytocin - neurophysin (OT-NP) |
| Expresión de antígenos | Leu 7 +, My23 +, CD11b + |
| Tumorigénico | Yes, in nude mice |
| Perfil mutacional | Mutation: SMARCA4, p.Glu1310Ter (c.3928G>T), homozygous; Mutation: PARD3B, Ex2-14del, homozygous; Mutation: TP53, p.Arg213Ter (c.637C>T), homozygous |
Manejo
| Medio de cultivo | Waymouth's MB 752/1 medium (We do not supply this product; please consider other suppliers. Please let us know if you need further assistance) |
|---|---|
| Suplementos | Supplement the medium with 10% FBS |
| Reactivo de disociación | Accutase |
| Renovación de fluidos | 2 times per week |
| Medio de congelación | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Descongelación y cultivo de células |
|
| Atmósfera de incubación | 37°C, 5% CO2, humidified atmosphere. |
| Condiciones de envío | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condiciones de almacenamiento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Control de calidad y análisis molecular
| Esterilidad | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificado de análisis (CoA)
| Número de lote | Tipo de certificado | Fecha | Número de catálogo |
|---|---|---|---|
| 305364-040425 | Certificado de análisis | 23. May. 2025 | 305364 |